Company news

Skye Bioscience, Inc. news in 2024

Skye Bioscience, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

December 18, 2024

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

November 17, 2024

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

November 13, 2024

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

November 6, 2024

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

November 3, 2024

Skye Bioscience to Announce Third Quarter 2024 Results

October 31, 2024

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

October 28, 2024

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

October 20, 2024

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

September 22, 2024

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

September 2, 2024

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

August 25, 2024

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

August 21, 2024

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

August 8, 2024

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

July 23, 2024

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

July 10, 2024

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

July 10, 2024

Skye Bioscience Uplists to The Nasdaq Global Market

April 9, 2024

Skye Bioscience Announces $40 Million Private Placement Equity Financing

March 10, 2024

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

March 3, 2024

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

February 25, 2024

Skye Bioscience to Present at Oppenheimer Investor Conference

February 6, 2024

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

January 28, 2024

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

January 8, 2024

Calls in 2024

Decks in 2024